HIGH BARRIER TO RESISTANCE

Treatment-naïve patIents

Reassurance for your patients out to Week 144

  • One participant with documented non-adherence developed resistance-associated mutations while taking DTG + 3TC separates
Baseline HIV-1 RNA (copies/mL)
Baseline CD4+ T-cell Count (cell/mm3)
Resistance Mutations Developed (Weeks)
DTG Susceptibility
Modified ART After Week 144
93,515 393

M184V
(Week 132)

R263R/K
(Week 144)
1.8-fold change DTG + DRV/c, regained virologic suppression

 

Few Confirmed Virological Withdrawals* at 144 weeks¹

img

DTG 50 mg + 3TC 300 mg used in the GEMINI studies.

*Patients met confirmed virological withdrawal criteria if a second and consecutive HIV-1 RNA value met any of the following definitions: decrease from baseline in HIV-1 RNA of <1 log10 copies/mL unless HIV-1 RNA of <200 copies/mL by Week 12; confirmed plasma HIV-1 RNA of ≥200 copies/mL after confirmed consecutive HIV-1 RNA <200 copies/mL.²

VIROLOGICALLY SUPPRESSED PATIENTs

Reassurance for your patients out to 96 Weeks

alt

No INI or NRTI Mutations Observed at Confirmed Virological Withdrawal*

img

*Patients met confirmed virological withdrawal criteria if they had 1 assessment with HIV-1 RNA ≥200 copies/ mL after Day 1 with an immediately prior HIV-1 RNA ≥50 copies/mL.³

References:

  1. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
  2. Cahn P, Sierra Madero J, Arribas JR, et al; for the GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143-155. doi:10.1016/S0140-6736(18)32462-0
  3. van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Slides O441.

 

PM-GB-HVU-WCNT-200001  | April 2021